Prostate Cancer

Today, there are more prostate cancer survivors than ever. It’s our job to keep that number growing.

Decades of great results.

Radiotherapy Clinics of Georgia (RCOG) treats many types of cancer, but specializes in curing prostate cancer. In fact, the ProstRcision^® treatment program at RCOG is the oldest and largest seed implant program for prostate cancer in the United States. For over 25 years, our doctors have worked to improve men’s chances for survival, while lowering the chance of side effects. And we’ve succeeded beyond our expectations.

The undeniable success of evidence-based medicine.

Since 1979, We have kept extensive data on each of our prostate cancer patients and compiled our observations into one of the largest computerized databases on prostate cancer in the U.S. Each man is tracked before and during treatment, and for years after he leaves. This database, which now represents more than 11,000 men, is vital to our success. Based on this data, our doctors can tailor each new patient’s treatment and provide him with his Individual Cure Rate.

To find out more and to get your Individual Cure Rate, visit ProstRcision.com.

Before you decide, be a sponge.

Our belief is that you should take the time to learn about your cancer and the options available. This puts you in control of the decision-making process and you’ll soon lose the feeling of helplessness that overcomes every man when he’s diagnosed with prostate cancer. As you’ve no doubt found, there’s plenty of information available. After some thorough research, you’ll go into your treatment knowing you made a well-informed choice.

For a detailed understanding of prostate cancer as well as a rational decision-making process regarding treatment based on cure of this disease, go to the Questions and Answers section of ProstRcision.com.

The numbers tell a promising story.

There are many statistics about prostate cancer, but we’ll focus on a few of the big ones. Let’s begin with the tough news: one in six men in the United States will get prostate cancer. With the exception of skin cancer, it’s the most common cancer found in men. Based on data provided by the American Cancer Society, estimates say that over more than 220,000 men will be diagnosed this year. But on the bright side, we’re winning the fight against this disease. While a lot of men are diagnosed, only one in 35 will die from prostate cancer. Clearly, early diagnosis, research and medical advances are making a difference. Today, more than two million men who have had prostate cancer are still living. At RCOG, we’re positive that we can make that number even greater.

Learn more at ProstRcision.com

---

1.Critz FA, and Levinson K.: 10-Year Disease-Free Survival Rates After Simultaneous Irradiation For Prostate Cancer With A Focus On Calculation Methodology. J Urol 172: 2232-2238, 2004. 2.Han M, Partin AW, Piantadosi S, Epstein JI, and Walsh PC.: Era Specific Biochemical Recurrence-Free Survival Following Radical Prostatectomy For Clinically Localized Prostate Cancer. J Urol 166: 416-419, 2001. Krygiel JM, Smith DS, Homan SM, Sumner W, Nease RF, Brownson RC and Catalona WJ.: Intermediate Term Biochemical progression Rates After Radical Prostatectomy and Radiotherapy In Patients With Screen Detected Prostate Cancer. J Urol 174: 126-130, 2005. Stephenson AJ, Scardino PT, Eastham JA, Bianco FJ, Dotan ZA, DiBlasio CJ, Reuther A, Klein EA, and Kattan MW. Postoperative Nomogram Predicting the 10-Year Probability of Prostate Cancer Recurrence After Radical Prostatectomy. J Clin. Onc. Vol. 23, (28): 7005-7012, 2005 Touijer K, Cronin AM, Vickers AJ, Secin FP, Bianco FJ, Guillonneau BD. Oncological Outcome After Laparoscopic Radical Prostatectomy: 10 Years Experience. J Urol 179, (4): 558, 2008 Badami KK, Kaul S, and Menon M.: Evolution Of Robotic Radical Prostatectomy. Assessment After 2766 Procedures. Cancer 110 (9): 1951 – 1958, 2007. 3.Kuban D, Thames H, Levy L, Horwitx E, Kupelian P, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, and Zietman A.: Failure Definition – Dependent Differences In Outcome Following Radiation For Localized Prostate Cancer: Can One Size Fit All? Int J Rad Onc Biol Phys 61 (2): 409-414, 2005. 4.Kuban DA, Levy LB, Potter L, Beyer DC, Blasko JC, Moran BJ, Ciezki JP, Zietman AL, Zelefsky MJ, Pisansky TM, Elshaikh M, and Horwitz EM.: Comparison Of Biochemical Failure Definitions For Permanent Prostate Brachytherapy. Int J Rad Onc Biol Phys. 65 (5): 1487-1493, 2006. 5.Ragde H, Elgamal AA, Snow PB, Brandt J, Bartolucci AA, Nadir BS, and Kirb LJ.: Ten-Year Disease Free Survival After Transperineal Sonography-Guided Iodine-125 Brachytherapy With Or Without 45-Gray External Beam Irradiation In The Treatment of Patients With Clinically Localized, Low to High Gleason Grade Prostate Carcinoma. Cancer 83 (5): 989-1001, 1998. 6.Jones JS, Rewcastle JC, Donnelly BJ, Lugnani FM, isters LL, and Katz AE.: Whole Gland Primary Prostate Cryoablation: Initial Results From the Bryo On-Line Data Registry. J Urol 180:554-558, 2008. 7.Demanes DJ, Rodrigues RR, Schour L, Brandt D, and Altieri G.: High-Dose –Rate Intensity-Modulated Brachytherapy With External Beam Radiotherapy For Prostate Cancer: California Endocurietherapy’s 10-Year Results. Int J Rad Onc Biol Phys, 61 (5): 1306-1316, 2005. 8.Slater JD, Rossi CJ, Yonemoto LT, Bush DA, Jabola BR, Levy RP, Grove RI, Preston W, and Slater JM.: Proton Therapy For Prostate Cancer: The Initial Loma Linda University Experience. Int J. Rad Onc Biol Phys. 59 (2): 348-352, 2004. 9.Koch MO, Gardner T, Cheng L, Fedewa RJ, Seip R, and Sangvhi NT.: Phase I/II Trial of High Intensity Focused Ultrasound for the Treatment of Previously Untreated Localized Prostate Cancer. J Urol 178: 2366-2371, 2007. 10.Bentzen SM, Wasserman TH. Editorial: Balancing on a Knife’s Edge: Evidence-Based Medicine and The Marketing of Health Techology. Int J Rad Onc Biol Phys vol. 72 (1), 2008.